Apogee Therapeutics, Inc. Common Stock (APGE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $135.07 (-0.01%), Market cap $6.21B, 52-week low–high $34.65 ~ $92.20.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial
Financial statements, price targets, institutional (13F) holdings and related news for Apogee Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Apogee Therapeutics, Inc. Common Stock trades at $135.07 (-0.01%). Real-time quotes and charts are available on BlackAll Trade.
Apogee Therapeutics, Inc. Common Stock has a market cap of about $6.21B.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary dise